...
机译:Sodium-Glucose Co-transporter 2 Inhibitors Versus Metformin as the First-Line Treatment for Type 2 Diabetes: Is It Time for a Revolution?
Aristotle University of Thessaloniki,Aristotle Univ Thessaloniki;
Dept Internal Med 1,Tzaneio Gen Hosp Piraeus;
Sch Med,Natl & Kapodistrian Univ Athens;
SGLT2 inhibitors; Metformin; Type 2 diabetes; Cardiovascular outcomes; METABOLIC OUTCOMES; SGLT2 INHIBITORS; EMPAGLIFLOZIN; MANAGEMENT; MORTALITY; BENEFITS; STILL; COST; RISK;